The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape
Open accessAbstract
Single genome sequencing of early HIV-1 genomes provides a sensitive, dynamic assessment of virus evolution and insight into the earliest anti-viral immune responses in vivo. By using this approach, together with deep sequencing, site-directed mutagenesis, antibody adsorptions and virus-entry assays, we found evidence in three subjects of neutralizing antibody (Nab) responses as early as 2 weeks post-seroconversion, with Nab titers as low as 1∶20 to 1∶50 (IC(50)) selecting for virus escape. In each of the subjects, Nabs targeted different regions of the HIV-1 envelope (Env) in a strain-specific, conformationally sensitive manner. In subject CH40, virus escape was first mediated by mutations in the V1 region of the Env, followed by V3. HIV-1 specific monoclonal antibodies from this subject mapped to an immunodominant region at the base of V3 and exhibited neutralizing patterns indistinguishable from polyclonal antibody responses, indicating V1-V3 interactions within the Env trimer. In subject CH77, escape mutations mapped to the V2 region of Env, several of which selected for alterations of glycosylation. And in subject CH58, escape mutations mapped to the Env outer domain. In all three subjects, initial Nab recognition was followed by sequential rounds of virus escape and Nab elicitation, with Nab escape variants exhibiting variable costs to replication fitness. Although delayed in comparison with autologous CD8 T-cell responses, our findings show that Nabs appear earlier in HIV-1 infection than previously recognized, target diverse sites on HIV-1 Env, and impede virus replication at surprisingly low titers. The unexpected in vivo sensitivity of early transmitted/founder virus to Nabs raises the possibility that similarly low concentrations of vaccine-induced Nabs could impair virus acquisition in natural HIV-1 transmission, where the risk of infection is low and the number of viruses responsible for transmission and productive clinical infection is typically one.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Broad neutralization coverage of HIV by multiple highly potent antibodies
Walker, L. M., Huber, M., Doores, K. J., Falkowska, E., Pejchal, R., Julien, J.-P., Wang, S.-K., Ramos, A., Chan-Hui, P.-Y., Moyle, M., et al. (2011) · Nature · doi:10.1038/nature10373 · Cited by 1,480
Self-citationStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationVaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829 · cited 1×
“Nabs constrain the replication of most viruses and are essential to the efficacy of most viral vaccines”
BackgroundDale, B. M., McNerney, G. P., Thompson, D. L., Hubner, W., de los Reyes, K., Chuang, F. Y. S., Huser, T., & Chen, B. K. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.10.015 · Cited by 133 · cited 1×
“This is at odds with the suggestion that ‘cell-to-cell’ spread of HIV-1 provides a mechanism for replicating virus to escape Nab or antiretroviral drug pressure [69,70].”
Result
Cited by
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar, K. J., Sneller, M. C., Harrison, L. J., Justement, J. S., Overton, E. T., Petrone, M. E., Salantes, D. B., Seamon, C. A., Scheinfeld, B., Kwan, R. W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1608243 · Cited by 455
Self-citationPrevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
Hraber, P., Seaman, M. S., Bailer, R. T., Mascola, J. R., Montefiori, D. C., & Korber, B. T. (2014) · AIDS · doi:10.1097/qad.0000000000000106 · Cited by 357
Self-citationStructural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321
Modeling the within-host dynamics of HIV infection
Perelson, A. S., & Ribeiro, R. M. (2013) · BMC Biology · doi:10.1186/1741-7007-11-96 · Cited by 283
Self-citation(2026) · doi:10.1073/pnas.2532810123 · Cited by 8
Metadata
- Authors
- Bar, K. J., Tsao, C.-Y., Iyer, S. S., Decker, J. M., Yang, Y., Bonsignori, M., Chen, X., Hwang, K.-K., Montefiori, D. C., Liao, H.-X., Hraber, P., Fischer, W., Li, H., Wang, S., Sterrett, S., Keele, B. F., Ganusov, V. V., Perelson, A. S., Korber, B. T., Georgiev, I., McLellan, J. S., Pavlicek, J. W., Gao, F., Haynes, B. F., Hahn, B. H., Kwong, P. D., & Shaw, G. M.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-31
- Volume
- 8
- Issue
- 5
- Pages
- e1002721
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W1996011751
- Cited by
- 180
- References
- 4
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.